What is clear is that Xarelto’s downward trend is expected to continue into 2025 at least. On the flip side, rising prostate cancer drug Nubeqa and chronic kidney disease med Kerendia should ...

Those drugs were Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog. CMS ...

Some of the drugs - including Eliquis, Xarelto and Jardiance - saw over one million Medicare enrolees file prescriptions for the medications in 2022. Medicare users who are enrolled in the plan's ...

Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances next year.

accusing the agency of blocking its plan to sell its psoriasis treatment Stelara and blood thinner Xarelto to some hospitals at full price before applying drug rebates. The 340B program has been ...

Partially offsetting this are declines in cardiovascular drug Xarelto due to loss of exclusivity events across various territories, which is putting pressure on both revenue growth and profit margins.